A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
The purpose of this study is to compare the efficacy of zipalertinib combined standard with adjuvant chemotherapy versus placebo combined standard with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Epistemonikos ID: a55511bfc8dfbd45b1b8015292981034078eb2b9
First added on: Aug 19, 2025